AI
KZR

Acuitas Investments’s Kezar Life Sciences KZR Stock Holding History

Acuitas Investments’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-122,752
Closed -$949K – 97
2024
Q3 		$949K Buy
122,752
+24,073
+24% +$145K 0.42% 79
2024
Q2 		$592K Buy
98,679
+29,596
+43% +$225K 0.32% 89
2024
Q1 		$623K Buy
+69,083
New +$629K 0.31% 92

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Acuitas Investments's KZR Position: Q4 2024 in Review

Acuitas Investments sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 122,752 shares — an estimated $949K sold.

Acuitas Investments first reported a position in KZR in Q1 2024 and held it in 3 quarters. The position peaked at $949K in Q3 2024. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • Acuitas Investments reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 122,752 Kezar Life Sciences shares in Q4 2024, an estimated $949K.
  • Acuitas Investments first reported a position in Kezar Life Sciences in Q1 2024 and held it in 3 quarters.
  • Acuitas Investments's Kezar Life Sciences position peaked at $949K in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.